The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Lot #	Exp. Date	Strength	Bottle Count	NDC
1329548A	06/2020	500 mg	100 Count	62037-571-01
1338302M	10/2020	500 mg	100 Count	62037-571-01
1348968M	10/2020	500 mg	100 Count	62037-571-01
1348969M	11/2020	500 mg	100 Count	62037-571-01
1348970M	10/2020	500 mg	100 Count	62037-571-01
1376339M	09/2021	500 mg	100 Count	62037-571-01
1323460M	06/2020	500 mg	1000 Count	62037-571-10
1330919M	06/2020	500 mg	1000 Count	62037-571-10
1338300A	10/2020	500 mg	1000 Count	62037-571-10
1341135M	12/2020	500 mg	1000 Count	62037-571-10
1391828M	11/2021	500 mg	1000 Count	62037-571-10
1333338M	08/2020	750 mg	100 Count	62037-577-01
1333339A	08/2020	750 mg	100 Count	62037-577-01
1354471A	02/2021	750 mg	1000 Count	62037-577-10

Teva Pharmaceuticals USA, Inc. (“Teva”) is recalling the above lots of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, 100 and 1000 count bottles that was distributed in United States under the Actavis Pharma, Inc. label to the consumer level. This recall is to the consumer level. The lots are being recalled due to detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI). Our records indicate we shipped this product from **01/08/2019** through **05/27/2020**.